This work is licensed under the Creative Commons Attribution 4.0 International License.
1. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Jul;75(7):1730–1741.ZhangJJDongXCaoYYClinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China..2020Jul;75(7):1730–1741.Search in Google Scholar
2. Meyer A, Buetti N, Houhou-Fidouh N, et al. HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients. Crit Care. 2021 Dec 6;25(1):417.MeyerABuettiNHouhou-FidouhNHSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients..2021Dec6;25(1):417.Search in Google Scholar
3. Ong DSY, Bonten MJM, Spitoni C, et al. Molecular Diagnosis and Risk Stratification of Sepsis Consortium. Epidemiology of Multiple Herpes Viremia in Previously Immunocompetent Patients With Septic Shock. Clin Infect Dis. 2017 May 1;64(9):1204–1210.OngDSYBontenMJMSpitoniCMolecular Diagnosis and Risk Stratification of Sepsis Consortium..2017May1;64(9):1204–1210.Search in Google Scholar
4. van den Brink JW, Simoons-Smit AM, Beishuizen A, Girbes AR, Strack van Schijndel RJ, Groeneveld AB. Respiratory herpes simplex virus type 1 infection/colonisation in the critically ill: marker or mediator? J Clin Virol. 2004 May;30(1):68–72.van den BrinkJWSimoons-SmitAMBeishuizenAGirbesARStrack van SchijndelRJGroeneveldAB.Respiratory herpes simplex virus type 1 infection/colonisation in the critically ill: marker or mediator?.2004May;30(1):68–72.Search in Google Scholar
5. Simoons-Smit AM, Kraan EM, Beishuizen A, Strack van Schijndel RJ, Vandenbroucke-Grauls CM. Herpes simplex virus type 1 and respiratory disease in critically-ill patients: Real pathogen or innocent bystander? Clin Microbiol Infect. 2006 Nov;12(11):1050–9.Simoons-SmitAMKraanEMBeishuizenAStrack van SchijndelRJVandenbroucke-GraulsCM.Herpes simplex virus type 1 and respiratory disease in critically-ill patients: Real pathogen or innocent bystander?.2006Nov;12(11):1050–9.Search in Google Scholar
6. Le Balc’h P, Pinceaux K, Pronier C, Seguin P, Tadié JM, Reizine F. Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. Crit Care. 2020 Aug 28;24(1):530.Le Balc’hPPinceauxKPronierCSeguinPTadiéJMReizineF.Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients..2020Aug28;24(1):530.Search in Google Scholar
7. Franceschini E, Cozzi-Lepri A, Santoro A, et al. Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study. Microorganisms. 2021 Sep 7;9(9):1896.FranceschiniECozzi-LepriASantoroAHerpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study..2021Sep7;9(9):1896.Search in Google Scholar
8. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The Role of Interleukin 6 During Viral Infections. Front Microbiol. 2019 May 10;10:1057.Velazquez-SalinasLVerdugo-RodriguezARodriguezLLBorcaMV.The Role of Interleukin 6 During Viral Infections..2019May10;10:1057.Search in Google Scholar
9. Murphy EA, Davis JM, Brown AS, Carmichael MD, Ghaffar A, Mayer EP. Effect of IL-6 deficiency on susceptibility to HSV-1 respiratory infection and intrinsic macrophage antiviral resistance. J Interferon Cytokine Res. 2008 Oct;28(10):589–95.MurphyEADavisJMBrownASCarmichaelMDGhaffarAMayerEP.Effect of IL-6 deficiency on susceptibility to HSV-1 respiratory infection and intrinsic macrophage antiviral resistance..2008Oct;28(10):589–95.Search in Google Scholar
10. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020 Aug 7;369(6504):718–724.HadjadjJYatimNBarnabeiLImpaired type I interferon activity and inflammatory responses in severe COVID-19 patients..2020Aug7;369(6504):718–724.Search in Google Scholar
11. Seeßle J, Hippchen T, Schnitzler P, Gsenger J, Giese T, Merle U. High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings. PLoS One. 2021 Jul 1;16(7):e0254129.SeeßleJHippchenTSchnitzlerPGsengerJGieseTMerleU.High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings..2021Jul1;16(7):e0254129.Search in Google Scholar
12. Gourd NM, Nikitas N. Multiple Organ Dysfunction Syndrome. J Intensive Care Med. 2020 Dec;35(12):1564–1575.GourdNMNikitasN.Multiple Organ Dysfunction Syndrome..2020Dec;35(12):1564–1575.Search in Google Scholar
13. Pfortmueller CA, Meisel C, Fux M, Schefold JC. Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers. Intensive Care Med Exp. 2017 Oct 23;5(1):49.PfortmuellerCAMeiselCFuxMSchefoldJC.Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers..2017Oct23;5(1):49.Search in Google Scholar
14. Luyt CE, Forel JM, Hajage D, et al. Preemptive Treatment for Herpesviridae Study Group, Réseau Européen de recherche en Ventilation Artificielle Network. Acyclovir for Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation: A Randomized Clinical Trial. JAMA Intern Med. 2020 Feb 1;180(2):263–272.LuytCEForelJMHajageDPreemptive Treatment for Herpesviridae Study Group, Réseau Européen de recherche en Ventilation Artificielle Network..2020Feb1;180(2):263–272.Search in Google Scholar
15. Hagel S, Scherag A, Schuierer L, Hoffmann R, Luyt CE, Pletz MW, Kesselmeier M, Weis S. Effect of antiviral therapy on the outcomes of mechanically ventilated patients with herpes simplex virus detected in the respiratory tract: a systematic review and meta-analysis. Crit Care. 2020 Sep 29;24(1):584.HagelSScheragASchuiererLHoffmannRLuytCEPletzMWKesselmeierMWeisS.Effect of antiviral therapy on the outcomes of mechanically ventilated patients with herpes simplex virus detected in the respiratory tract: a systematic review and meta-analysis..2020Sep29;24(1):584.Search in Google Scholar